While EGFR mutation status is commonly used as a therapeutic marker for TKIs in treating lung cancer, our findings indicated that the expression levels of EGFR in tumors are still critical for survival, especially in LUAD patients, suggesting a potential role of TKI-insensitive EGFR signaling in LUADs. The gene discussed is EGFR; the disease is lung cancer.